Brought to you by 
Genzyme licenses TKT's Hunter syndrome candidate
26 Jan 2015
Executive Summary
In a deal that brings two competitors together and settles long-standing litigation between them, Genzyme licensed the rights to develop and sell Transkaryotic Therapies' Phase III enzyme replacement therapy for Hunter syndrome, iduronate-2-sulfatase (I2S), in Japan and other territories within Asia and the Pacific Rim, including Australia and China.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme licenses TKT's Hunter syndrome candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice